Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements
Eagle Pharmaceuticals (OTCMKTS: EGRX) announced that its unaudited financial statements for the three months ended March 31, 2025 are available online. The documents can be accessed at the company's investor events and presentations page for review by shareholders and analysts.
Eagle Pharmaceuticals (OTCMKTS: EGRX) ha annunciato che i bilanci non revisionati relativi ai tre mesi terminati il 31 marzo 2025 sono disponibili online. I documenti possono consultarsi nella pagina degli eventi e delle presentazioni agli investitori dell'azienda, per la revisione da parte di azionisti e analisti.
Eagle Pharmaceuticals (OTCMKTS: EGRX) anunció que sus estados financieros no auditados correspondientes a los tres meses terminados el 31 de marzo de 2025 están disponibles en línea. Los documentos pueden consultarse en la página de eventos y presentaciones para inversionistas de la empresa, para revisión por accionistas y analistas.
Eagle Pharmaceuticals (OTCMKTS: EGRX)는 감사되지 않은 재무제표가 2025년 3월 31일에 종료된 3개월분으로 온라인에서 이용 가능하다고 발표했다. 이 문서는 주주 및 애널리스트의 검토를 위해 회사의 투자자 행사 및 프레젠테이션 페이지에서 확인할 수 있다.
Eagle Pharmaceuticals (OTCMKTS: EGRX) a annoncé que ses états financiers non audités pour les trois mois se terminant le 31 mars 2025 sont disponibles en ligne. Les documents peuvent être consultés sur la page des événements et présentations destinées aux investisseurs de l'entreprise, pour examen par les actionnaires et les analystes.
Eagle Pharmaceuticals (OTCMKTS: EGRX) kündigte an, dass seine ungeprüften Bilanzzahlen für die drei Monate bis zum 31. März 2025 online verfügbar sind. Die Dokumente können auf der Seite des Unternehmens zu Investorenveranstaltungen und Präsentationen von Aktionären und Analysten eingesehen werden.
Eagle Pharmaceuticals (OTCMKTS: EGRX) أعلنت أن البيانات المالية غير المراجعة للثلاثة أشهر المنتهية في 31 مارس 2025 متاحة عبر الإنترنت. يمكن الوصول إلى المستندات من صفحة الشركة الخاصة بالفعاليات والعروض التقديمية للمستثمرين للمراجعة من قبل المساهمين والمحللين.
Eagle Pharmaceuticals (OTCMKTS: EGRX) 发布其 未审计的财务报表，涵盖截至 2025年3月31日 的三个月。相关文件可在公司投资者活动与演示页面供股东与分析师查看。
- None.
- None.
WOODCLIFF LAKE, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that the Company’s unaudited financial statements for the three months ended March 31, 2025, are available at https://investor.eagleus.com/events-presentations.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), and BYFAVO® and BARHEMSYS® through its wholly owned subsidiary Acacia Pharma Inc. Eagle’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states, and the company is focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. Additional information is available on Eagle’s website at www.eagleus.com.
Investor Relations Contact
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
Where can I find Eagle Pharmaceuticals (EGRX) unaudited Q1 2025 financial statements?
What period do the available Eagle Pharmaceuticals (EGRX) statements cover?
Are the Q1 2025 financial statements for Eagle Pharmaceuticals (EGRX) audited?
Do the unaudited Q1 2025 statements from Eagle Pharmaceuticals (EGRX) include earnings or guidance?
How should investors use Eagle Pharmaceuticals (EGRX) unaudited financial statements dated March 31, 2025?
Who can I contact for more information about Eagle Pharmaceuticals (EGRX) financial disclosures?
